Atherosclerosis Plus (Oct 2021)

Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis

  • Duygu Kocyigit,
  • Francesca Zimetti,
  • Kadri M. Gurses,
  • Ilaria Zanotti,
  • Cinzia Marchi,
  • Marcus Ståhlman,
  • Jan Borén,
  • Hande Canpinar,
  • Mehmet F.T. Soyal,
  • Dicle Guc,
  • Tuncay Hazirolan,
  • Necla Ozer,
  • Lale Tokgozoglu

Journal volume & issue
Vol. 44
pp. 18 – 24

Abstract

Read online

Background and aims: Cholesterol efflux capacity is a functional property of high-density lipoproteins (HDL) reflecting the efficiency of the atheroprotective reverse cholesterol transport process in humans. Its relationship with calcific aortic valve stenosis (CAVS) has not been fully assessed yet. Methods: We evaluated HDL-CEC in a patient population with varying degrees of aortic valvular calcific disease, assessed using echocardiography and cardiac computed tomography. Measurement of biomarkers that reflect osteogenic and tissue remodeling, along with dietary and gut microbiota-derived metabolites were performed. Results: Patients with moderate-severe CAVS had significantly lower HDL-CEC compared to both control and aortic sclerosis subjects (mean: 6.09%, 7.32% and 7.26%, respectively). HDL-CEC displayed negative correlations with peak aortic jet velocity and aortic valve calcium score, indexes of CAVS severity (ρ = -0.298, p = 0.002 and ρ = -0.358, p = 0.005, respectively). In multivariable regression model, HDL-CEC had independent association with aortic valve calcium score (B: -0.053, SE: 0.014, p < 0.001), GFR (B: -0.034, SE: 0.012, p = 0.007), as well as with levels of total cholesterol (B: 0.018, SE: 0.005, p = 0.002). Conclusion: These results indicate an impairment of HDL-CEC in moderate-severe CAVS and may contribute to identify potential novel targets for CAVS management.

Keywords